-
1-(butan-2-yl)-4-{4-[4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
-
ChemBase ID:
106199
-
Molecular Formular:
C35H38Cl2N8O4
-
Molecular Mass:
705.63342
-
Monoisotopic Mass:
704.2393071
-
SMILES and InChIs
SMILES:
CCC(C)n1ncn(c1=O)c1ccc(cc1)N1CCN(CC1)c1ccc(OCC2COC(Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1
Canonical SMILES:
CCC(n1ncn(c1=O)c1ccc(cc1)N1CCN(CC1)c1ccc(cc1)OCC1COC(O1)(Cn1cncn1)c1ccc(cc1Cl)Cl)C
InChI:
InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3
InChIKey:
VHVPQPYKVGDNFY-UHFFFAOYSA-N
-
Cite this record
CBID:106199 http://www.chembase.cn/molecule-106199.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
1-(butan-2-yl)-4-{4-[4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
|
|
|
IUPAC Traditional name
|
@itraconazole
|
itraconazole
|
|
|
Synonyms
|
Oriconazole, R51211, Sporanox
|
ITRACONAZOLE
|
Oriconazole
|
R51211
|
Sporanox
|
Itraconazole
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
H Acceptors
|
9
|
H Donor
|
0
|
LogD (pH = 5.5)
|
7.3001556
|
LogD (pH = 7.4)
|
7.3112283
|
Log P
|
7.3113713
|
Molar Refractivity
|
200.4 cm3
|
Polarizability
|
71.596016 Å3
|
Polar Surface Area
|
100.79 Å2
|
Rotatable Bonds
|
11
|
Lipinski's Rule of Five
|
false
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
I6657
|
Application Itraconazole is a triazole antifungal agent. It is used to inhibit cytochrome P-450-dependent enzymes and ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis, and aspergillosis. It′s different formulations are used to study Candida strains in murine invasive infections1. It has been used to study proliferative changes of the forestomach mucosa in alloxan-induced diabetic rats2. Biochem/physiol Actions Itraconazole inhibits cytochrome P-450-dependent enzymes which results in the inhibition of ergosterol synthesis. It does so by interacting with 14-α demethylase, which is a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. Ergosterol is a crucial compenent of fungal cell membranes. Therefore, it′s inhibition results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and phospholipid biosynthesis. |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Chau, A.S., "Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae." Antimicrob. Agents Chemother. 50, 3917-3919, (2006)
- • Xiong, Q., et al., "Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors." Antimicrob. Agents Chemother. 49, 518-524, (2005)
- • Sabatelli, F., et al., "In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts." Antimicrob. Agents Chemother. 50, 2009-2015, (2006)
- • Vanden Bossche, H., et al., "Effects of itraconazole on cytochrome P-450-dependent sterol 14α-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans." Antimicrob. Agents Chemother. 37, 2101-2105, (1993)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent